### Thursday, October 24, 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM – 7:30 AM</td>
<td>Registration &amp; Continental Breakfast</td>
</tr>
<tr>
<td>7:30 AM – 7:45 AM</td>
<td>Welcome Announcements</td>
</tr>
</tbody>
</table>
| 7:45 AM – 8:45 AM | **Trends in the Use of Psychopharmacology in Children Adolescents in Texas**  
Emilie Attwell Becker, MD  
Medicaid Chip Mental Health Director • Texas Health and Human Services  
- Describe of prescribing changes for children in Texas Medicaid  
- Explain legislative initiatives to monitor children's psychotropic prescribing  
- Describe the cost of psychotropic medicine in the public health system |
| 8:45 AM – 9:45 AM | **Mental Health in the Patient Centered Medical Home**  
Tera Moore, PharmD  
Adjunct Assistant Professor • The University of Texas at Austin College of Pharmacy  
- Explain the model and purpose of the patient centered medical home  
- Describe how to integrate mental health in a multidisciplinary ambulatory environment |
| 9:45 AM – 10:00 AM | Break                                                                                                       |
| 10:00 AM – 11:00 AM | **Traumatic Brain Injury Treatment Update**  
Kimberly Arlinghaus, MD  
Medical Director of Psychiatry and Behavioral Health • Lone Star Circle of Care  
Professor of Psychiatry and Behavioral Science • Texas A&M College of Medicine  
- Distinguish between mild, moderate and severe traumatic brain injury  
- Describe pathophysiology of traumatic brain injury and its sequelae  
- Explain management of Traumatic Brain Injury and its sequelae  
- Describe Texas law requiring evaluation for concussion and how it impacts patient care |
| 11:00 AM – 12:00 PM | **Psychotropic New Drug Update**  
Stephen R. Saklad, PharmD, BCPP  
Clinical Pharmacologist • UTHSCSA & Texas Department of State Health Services  
Director • Psychiatric Pharmacy Program UTHSCSA Pharmacotherapy Education and Research Center  
Clinical Professor • The University of Texas at Austin College of Pharmacy  
Adjoint Associate Professor • UTHSCSA School of Medicine  
- Describe the pharmacology, adverse effects, drug interactions, therapeutic uses and dosing of selected psychiatric drugs recently marketed as well as drugs approaching the market  
- List key trends in new drug development |
| 12:00 PM – 12:30 PM | Pick up Lunch and Return to Classroom for Working Lunch Presentation |

Program provides 15 hours CE for CPE, CME, CNE, Social Work • APA Accredited 11.5 hrs sessions indicated below by *
### Program Overview

**12:30 PM – 1:00 PM**

**Working Lunch**

0.50 CE

**25 Year Retrospective of Psychiatric Pharmacotherapy, Where We Were, and Where We are Headed**

Dr. Larry Ereshefsky, PharmD  
Chief Scientific Officer • California Clinical Trials  
Vice President, Principal Clinical Pharmacologist, and Psychiatric Therapeutics Expert • PAREXEL International; and Adjunct Professor of Psychiatry • UTHSCSA

- Describe the major advances in psychiatric pharmacotherapy practice over the past 25 years in relation to current practice and innovations
- List key current trends in psychiatric pharmacotherapy practices
- Describe the potential impact of current psychopharmacology innovations in the near future

**1:00 PM – 2:00 PM**

**Interprofessional Panel • Continued Discussion of 25th Year Retrospective of Psychiatric Pharmacotherapy**

Panelist: Larry Ereshefsky • Stephen R. Saklad • Emilie Becker • James Bray • Maria Ostrander • Tawny Smith

- Identify trends presented in relation to various professions
- Describe patient improvement treatments due to interprofessional approach

**2:00 PM – 3:00 PM**

**Break**

**3:00 PM – 3:15 PM**

**Overview and Assessment of Drug-induced Movement Disorders**

Roger Sommi, PharmD, BCPP, FCCP  
Professor of Pharmacy Practice and Psychiatry • University of Missouri-Kansas City Schools of Pharmacy and Medicine

- Identify the characteristics of tardive dyskinesia, pseudoparkinsonism, & akathisia
- Identify the common movement disorders rating scales and use in clinical practice

**3:15 PM – 4:15 PM**

**Micronutrient Deficiencies: Clinical Issues and Developments**

Tom Brown, MD  
Psychiatry Consultation-Liaison Service • Audie L. Murphy Memorial VAMC

- Identify pathways to malnutrition
- Describe approaches to managing vitamin C deficiency
- Describe approaches to managing thiamine deficiency

**4:15 PM – 5:15 PM**

**Advances in the Treatment of Alzheimer's Disease and Other Dementias**

Dr. Larry Ereshefsky, PharmD  
Chief Scientific Officer • California Clinical Trials  
Vice President, Principal Clinical Pharmacologist, and Psychiatric Therapeutics Expert • PAREXEL International; and Adjunct Professor of Psychiatry • UTHSCSA

- Describe approaches, using Alzheimer's disease as an illustrative challenge for CNS drug development
- Describe the use of biomarkers as a tool to demonstrate proof of drug mechanism and to determine clinically useful doses.
- List biomarkers that are likely to be widely implemented in the next decade
- Explain how new insights into the course of Alzheimer's Disease have modified diagnosis and treatment strategies.
- Describe the 'future' of treatment for Alzheimer's Disease, especially the role of pharmacists in Amyloid/Tau screening for early detection and prevention of the disorder

**5:15 PM – 6:30 PM**

**Happy Hour Reception • Celebration of 25th Conference Anniversary**

Please join us in the Dover's Room (Across from the Hotel Lobby)

---

Program provides 15 hours CE for CPE, CME, CNE, Social Work • APA Accredited 11.5 hrs sessions indicated below by *

The Psychiatric Pharmacotherapy Update is a program of The University of Texas at Austin College of Pharmacy, Continuing Pharmacy Education Office.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>7:30 AM – 8:00 AM</strong></td>
<td>Continental Breakfast</td>
</tr>
<tr>
<td><strong>8:00 AM – 8:15 AM</strong></td>
<td>Morning Announcements</td>
</tr>
<tr>
<td><strong>8:15 AM – 9:15 AM</strong></td>
<td>Schizophrenia Update*</td>
</tr>
<tr>
<td><strong>9:15 AM – 10:15 AM</strong></td>
<td>Bipolar Disorder Update</td>
</tr>
<tr>
<td><strong>10:15 AM – 10:30 AM</strong></td>
<td>Break</td>
</tr>
<tr>
<td><strong>10:30 AM – 11:30 AM</strong></td>
<td>Depression Update: Focus on Treatment Resistant Depression and Off-Label Drug Use*</td>
</tr>
<tr>
<td><strong>11:30 AM – 12:00 PM</strong></td>
<td>Pick up Lunch and Return to Classroom for Working Lunch Presentation</td>
</tr>
<tr>
<td><strong>12:00 PM – 1:00 PM</strong></td>
<td>Update on Street Drugs &amp; Substance Abuse and Treatments*</td>
</tr>
<tr>
<td><strong>1:00 PM – 1:30 PM</strong></td>
<td>Interprofessional Panel • Continued Discussion of Substance Abuse and Treatments*</td>
</tr>
<tr>
<td><strong>1:30 PM – 1:45 PM</strong></td>
<td>Break</td>
</tr>
<tr>
<td><strong>1:45 PM – 2:45 PM</strong></td>
<td>Neurobiology Update*</td>
</tr>
<tr>
<td><strong>2:45 PM – 3:45 PM</strong></td>
<td>Drug Therapy-Related Issues in Patients Who Received Bariatric Surgery</td>
</tr>
<tr>
<td><strong>3:45 PM – 4:00 PM</strong></td>
<td>Seminar Application, Evaluation, Closing</td>
</tr>
</tbody>
</table>

Program provides 15 hours CE for CPE, CME, CNE, Social Work • APA Accredited 11.5 hrs sessions indicated below by *

The Psychiatric Pharmacotherapy Update is a program of The University of Texas at Austin College of Pharmacy, Continuing Pharmacy Education Office

---

**Schizophrenia Update**

*Troy Moore, PharmD, M.S., BCPP*

Director • ASHP PGY-2 Psychiatric Pharmacy Residency • South Texas Veterans Healthcare System

- Explain current trends in treatment of Schizophrenia
- Cite evidence supporting the cognitive benefits of antipsychotics
- Describe potential functional gains demonstrated by atypical antipsychotics

**Bipolar Disorder Update**

*Jana Shults, PharmD*

Clinical Pharmacy Specialist – Mental Health • South Texas Veterans Healthcare System

- Identify paradigm shifts in the assessment / treatment of bipolar disorder
- Describe new treatment strategies in the treatment of bipolar disorder

---

**Depression Update: Focus on Treatment Resistant Depression and Off-Label Drug Use**

*Madhukar Trivedi, MD*

Professor of Psychiatry • UT Southwestern Medical Center

- Recall the definitions and clinical challenges of managing treatment-resistant depression.
- Compare the pharmacologic agents that have shown to be efficacious in treatment-resistant depression
- Identify the recent advances in non-pharmacologic strategies to manage treatment-resistant depression

**Update on Street Drugs & Substance Abuse and Treatments**

*April Cope, PharmD, BCPP*

Clinical Pharmacy Specialist in Behavioral Health • James E Van Zandt VA Medical Center

- Describe current trends of street drugs
- Explain issues and trends with use of Bath Salts

**Interprofessional Panel • Continued Discussion of Substance Abuse and Treatments**

Panelist: April Cope, PharmD • Francis Holland, BSN • Ramona Rogers, MD • Troy Moore, PharmD

- Describe treatment options for recovery
- Explain interprofessional team approach

**Neurobiology Update**

*Pedro L. Delgado, MD*

Professor and Chairman • Dielmann Distinguished Chair in Psychiatry • UTHSCSA

- Identify methods that genetic and environmental influences interact to increase mental disorders
- List the implications of genetic findings to future treatment of mental disorders

**Drug Therapy-Related Issues in Patients Who Received Bariatric Surgery**

*Lingtak-Neander Chan, PharmD, BCNSP*

Associate Professor of Pharmacy • University of Washington School of Pharmacy

- Explain how pharmacotherapy is affected by bariatric surgery
- Describe what pharmacotherapeutic strategies may be necessary to reduce the complications associated with bariatric surgery procedures
- Describe how each of the established bariatric procedures alters pharmacokinetics